Liaoning Cheng Da

Name

Liaoning Cheng Da

Legal name

辽宁成大股份有限公司

Website

https://chengda.com.cn

Company type

Public

Founded year

1991

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Diversified Holding Company (Biopharmaceuticals, Trade, Financial Investment, Energy)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Travel & Tropical Disease Vaccines (HLAIAEAE)

akta.pro secondary industries

Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

Keywords

• Human rabies vaccines
• Biopharmaceutical manufacturing
• International textile trade
• Bulk commodity trading
• Financial investment holdings

Headquarters

HQ city

Dalian Shi

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Operations

Revenue model

1. 生物制药 (Biopharmaceuticals): Revenue from human rabies vaccines and Japanese encephalitis vaccines through subsidiary Chengda Biologics (688739.SH)
2. 金融投资 (Financial Investment): Investment returns from holdings in Guangfa Securities (second largest shareholder) and Zhonghua Insurance (second largest shareholder)
3. 供应链贸易 (Supply Chain/Trade): Import/export trade including textiles, garments, coal, steel, and aquatic products through subsidiaries Chengda International, Chengda Development, and Chengda Steel
4. 能源开发 (Energy Development): Oil shale mining and shale oil production through Xinjiang Baoming subsidiary

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Liaoning Cheng Da is a diversified holding company that develops, manufactures, and sells human rabies vaccines (Vero cell and human diploid cell types) through its majority-owned subsidiary Chengda Bio (STAR Market: 688739), the world's largest supplier of human rabies vaccines. The company also trades textiles, garments, steel, and bulk commodities internationally, holds strategic stakes in GF Securities and China United Insurance, and mines oil shale in Xinjiang.

Product overview

辽宁成大是一家以生物制药为核心、金融投资与供应链贸易双轮驱动的综合型上市企业集团。旗下辽宁成大生物股份有限公司专注于人用疫苗研发与生产，拥有成大速达®（Vero细胞狂犬病疫苗）和成大安欣®（人二倍体细胞狂犬病疫苗）两大核心产品，是全球最大的人用狂犬病疫苗供应商；医疗服务板块包括成大医院和成大医疗；供应链贸易板块涵盖成大国际（纺织服装进出口）、成大发展（大宗商品贸易）、成大钢铁三大子公司；能源开发板块以新疆宝明油页岩开发利用为主；金融投资板块参控股广发证券、中华保险、华盖资本等持牌金融机构。

Differentiator

Problem solved

Functional benefit

Brands

• 成大速达 (Chengda Suda): Vero cell-based human rabies vaccine; China's first domestically manufactured rabies vaccine using bioreactor preparation; approved for three post-exposure immunization procedures including the simplified 4-injection schedule.
• 成大安欣 (Chengda Anxin)
• 成大沿海基金 (Chengda Coastal Fund)
• 成大方圆 (Chengda Dafangyuan)

Products and services

• Chengda Suda (成大速达) Vero Cell Human Rabies Vaccine China's first rabies vaccine using bioreactor-scale manufacturing process, Vero cell-based, supporting three post-exposure immunization schedules (5-dose, 2-1-1 Zagreb, and simplified 4-dose). Globally supplied with cumulative volumes exceeding 500 million doses. Marketed to government CDC centers and public health authorities for mass immunization.
• Chengda Anxin (成大安欣) Human Diploid Cell Rabies Vaccine China's first approved simplified 4-dose immunization procedure human diploid cell rabies vaccine, covering three immunization schedules (5-dose, 2-1-1, simplified 4-dose) with completion possible in 14 days. A premium-tier freeze-dried vaccine for post-exposure prophylaxis.
• Chengda Bio Inactivated Japanese Encephalitis Vaccine (乙脑灭活疫苗) The only domestically produced inactivated Japanese encephalitis vaccine currently sold in China, manufactured using Vero cell substrate, targeting endemic JE prevention in pediatric and at-risk populations.
• High-Dose Influenza Virus Split Vaccine (流感病毒裂解疫苗/高剂量) An influenza virus split vaccine with antigen content four times that of standard-dose influenza vaccines, intended for elderly populations aged 60 years and above. Approved to begin clinical trials in February 2026 by the NMPA.
• Chengda International Textile and Garment Trade (成大国际) One of China's largest textile and garment import/export companies, providing integrated R&D design, front-end marketing, cross-border procurement, and logistics services. Customers in Japan, North America, South America, Europe and 50+ countries/regions.
• Chengda Development Commodity Trade (成大发展) Professional bulk commodity trader focused on agricultural products and coal domestic and international trade, with annual sales of 40-60 billion yuan and procurement/sales networks in 50+ countries.
• Chengda Steel Trade (成大钢铁) One of the largest and most influential steel trade enterprises in Northeast China, with annual trade volume exceeding 10 billion yuan and a sales network covering major regions nationwide.
• Xinjiang Baoming Oil Shale Mining and Shale Oil Production (新疆宝明) One of China's leading oil shale development enterprises, holding 70 square kilometers of oil shale resources in Jimsar County, Xinjiang, including mining rights at Shichanggou and exploration rights at Mutasi, Wujiawan, and Baiyanghe. Currently focused on Shichanggou project construction and oil extraction.
• Chengda Hospital (成大医院) Large Class III hospital planned for development starting in Dalian's Donggang business district, with specialties in oncology, cardiovascular disease, obstetrics/gynecology, and health checkups. A joint venture between Chengda Medical Services subsidiary and other shareholders.
• Chengda Coastal Industry Fund (成大沿海基金) Private equity fund management platform registered as P1007964, managing multiple private equity funds focused on intelligent manufacturing, TMT, healthcare, consumption, and environmental protection sectors.

Quantifiable outcome

• 500 million+ doses of rabies vaccine supplied globally
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Six partnerships are on record, tiered strategic and minor.

• 中国科学院微生物研究所 (Chinese Academy of Sciences Institute of Microbiology)strategicStrategic or Co-development Partner · 30 December 2025Jointly established 'Synthetic Immunology and Vaccine Manufacturing Beijing Key Laboratory' with academician Gao Fu. Focuses on mucosal immunity mechanisms, broad-spectrum vaccine design using AI-optimized epitope technology, and novel adjuvant research.
• 中科紫东太初 (中科紫东太初(北京)科技有限公司)Technology or Integration · 21 October 2025AI+ Vaccine R&D Joint Laboratory established for AI-powered vaccine research including data integration, technology development, service empowerment and ecosystem building.
• 北京彼得·德鲁克管理研修学院 (Beijing Peter Drucker Management Academy)minorStrategic or Co-development Partner · 1 June 2019Strategic partnership established for management education and leadership development, leveraging Drucker's management philosophy.
• 大连医科大学 (Dalian Medical University)minorStrategic or Co-development Partner · 1 September 2017Five-year strategic cooperation agreement signed in 2017 for medical health services,产学研 cooperation, joint talent cultivation and innovation entrepreneurship practice. Includes imaging diagnostics, medical testing, pathology platforms and specialist hospitals.
• 日本伊藤忠商事株式会社 (Itochu Corporation)minorStrategic or Co-development Partner · 1 May 2014Joint venture Kangxinmeij (康心美) Japanese-style pharmacy chain established with Japanese Itochu (Fortune 500), Efurēsa赛控集团, and cocokara fine (second largest Japanese pharmacy chain). Total investment 30 million yuan.
• 沈阳药科大学 (Shenyang Pharmaceutical University)minorStrategic or Co-development PartnerEstablished Chengda Scholarship of 3 million yuan for pharmaceutical education support.

Scale indicators10 records

Recent moves10 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liaoning Cheng Da